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The word “Prion” refers to self-perpetuating protein aggregates that cause 
neurodegenerative diseases in mammals. It is a protein isoform that has undergone a 
conformational change which converts the normal form of the protein into the 




] prion is the prion isoform of Sup35 protein, a translation termination 
factor eRF3. It has been suggested that prion [PSI
+
] is controlled by the ensemble of 
chaperones with Hsp104 playing the major role. The previous work performed in the 
Chernoff’s lab showed that the defective GET pathway caused by get2∆ led to the 
defect in [PSI
+
] curing by excess Hsp104. The GET pathway is a system responsible 
for transporting newly synthesized TA-protein to the ER membrane, and the 
components which have been proven to be involved in this pathway include: Get1, 
Get2, Get3, Get4, Get5 and Sgt2.  
 
In this study we describe the mechanism underlying the effect of the defective GET 
pathway on [PSI
+
]. We demonstrate that Sgt2, one of the components of GET pathway, 




] strains through its prion domain. 
Overproduction of Sgt2 and Hsp70-Ssa is triggered by the defective GET pathway and 
 
leads to the protection of [PSI
+
] aggregates from curing by excess Hsp104. We show 




1.1 Prions  
In molecular biology, it was well known that the information is transmitted only by 
nucleic acids like DNA and RNA. However, the discovery of the protein-based 
inheritance led to a change in the central dogma of molecular biology. The name for 
these heritable protein determinants - prion- is a portmanteau derived from the 
combination of two words protein and infection, since they have been proven to be an 
infectious agent in mammals
1
. We now know that the inheritable information can be 
efficiently transferred from cell to cell though cytosol by prion proteins. Neither the 
original nucleotide sequence of the gene or mRNA nor the derivative amino acid 
sequence of the prion protein is changed compared to the normal cellular form of the 
same protein. Nevertheless, the prion is efficiently transmitted to the progeny in a 




The term prion was originally introduced over 30 years ago by S. Prusiner to explain 
the unusual transmission pattern of neurodegenerative diseases
1
. Prion is a protein 
isoform that has undergone a conformational change which converts the normal form 
of the protein into the infectious form with the same amino acid sequence. This change 
 
diminishes its own ability to perform the normal function but the infectious ability 
enables it to propagate 
3,4
. (see Figure 1). 
 
 
Figure 1 Prion model  
Aggregated prion form of the protein (square) converts a non-prion form (circle) of the 
same protein. 
 
Prion propagates by transmitting a misfolded protein state in an infectious way. When 
prion enters an organism, it induces existing, properly-folded proteins to convert into 
the prion form. Prion acts as a template to guide the alternative folding of the native 
protein into prion conformation. These newly-formed prions can then go on to convert 
more proteins and a chain reaction is triggered that produces large amounts of the prion 
form. All known prions induce the formation of amyloids, the extremely stable fibrils 




1.2 Prion diseases 
A big part of all known mammalian prion diseases, collectively called transmissible 
spongiform encephalopathies (TSEs)
7
, such as “mad cow disease”, or bovine spongiform 
encephalopathy (BSE), scrapie disease of sheep, and human Creutzfeldt-Jacob disease, are 
 
untreatable and fatal and characterized by spongiform degeneration of the brain. Other 
human manifestations include Gerstmann-Straussler-Scheinker disease (GSS), Kuru, 




These prion diseases are caused by the so-called prion protein, PrP. The amyloid 
structure of prion is extremely stable and accumulates in infected tissue, and prion 
diseases are caused by prion protein aggregating extracellularly within the central 
nervous system and forming amyloid plaques, which disrupt the normal tissue structure. 
This disruption is characterized by "holes" in the tissue with resultant spongy 
architecture due to the vacuole formation in the neurons
6,9,11. Also, it has been 
proposed that neurodegeneration caused by prions may be related to the lost of normal 
function of PrP
12
. Evidence showed that losing PrP may have an abnormal function in 
maintenance of long-term memory
13,14
. Moreover, studies showed that PrP expression 
on stem cells is necessary for an organism's self-renewal of bone marrow
15
. However, 
the real physiological function of the prion protein remains a controversial matter. 
 
The properties of PrP are very similar to those seen in various non-infectious amyloids 
resulting from conversion of certain proteins or their fragments from the normally soluble 
form to the insoluble fibrils or plaques, which place prion diseases into the large and 
 
heterogeneous group of amyloid diseases, including about 20 human diseases, such as 
Alzheimer’s disease, Huntington’s disease and Parkinson’s diseases16-18. These diseases 
occur widely in humans and other mammals, and the mechanism by which such 
conformational switches lead to aggregate formation and disease remains unknown. 
The auto-catalyzed misfolding, perpetuation of wrong conformation and aggregation of 
proteins in these amyloid diseases are consistent with the prion concept observed in 
TSEs, which make studies related to prion not only benefit the understanding of TSEs 
but also amyloid diseases. 
 
1.3 Yeast prions 
Investigating prion in mammals is a tough task since the key experiments are often 
infeasible. Fortunately, there is a simple eukaryotic model for researching prion 
biology - the budding yeast Saccharomyces cerevisiae. Yeast were shown to have 
multiple factors with typical prion behavior, which makes them a very simple and 
convenient model for studying the mammalian prions
19
. Yeast cells are easily 
manipulated and cultured in the laboratory, and those powerful standard techniques 
developed in yeast, such as yeast two-hybrid, synthetic genetic array analysis and 
tetrad analysis, could be used to understand the mechanism of prion propagation. 
Although prions in yeast are sometimes associated with certain toxicity phenomena, 
 
however, by themselves, yeast prions are not pathogenic. 
 
A set of genetic criteria was proposed for researchers to identify prions in yeast. The 
criteria include: non-Mendelian inheritance, reversible curability and inducibility by 
overexpressing the normal protein isoform. Three of the best-characterized prions of S. 




], and all of them meet the criteria for 
identifying prions in yeast (see Table 1). They are inherited in a non-Mendelian 
manner and require specific cellular proteins for maintenance (Ura2 gene in case of 
[URE3], Sup35 gene in case of [PSI
+
], and Rnq1 in case of [PIN
+
]). They are 
reversibly curable using agents such as guanidine hydrochloride, and the prion form 










Table 1 Known yeast prions 
Prion  Protein  Normal Function  
[URE3]  Ure2  Nitrogen catabolism repressor  
[PIN
+
]  Rnq1  Unknown  
[PSI
+
]  Sup35  Translation termination factor  
[MCA
+
]  Mca1  Putative yeast caspase  
[Swi
+
]  Swi1  Chromatin remodeling  
[OCT
+
]  Cyc8  Transcriptional repressor  
[MOT3
+
]  Mot3  Nuclear transcription factor  
 
[URE3] is the prion form of the protein Ure2 that is a nitrogen catabolic repressor. 
Because of the partial loss of function of Ure2 in the presence of [URE3], cells are able 
to uptake poor nitrogen sources of uracil, which gives a prion the phenotype of growth 




] is the prion form of the protein Rnq1 with unknown 
normal cellular function. The presence of the prion [PIN
+
] facilitates the de novo 






] is the prion forms of the protein Sup35 that 
functions as a translation termination factor eRF3. The presence of [PSI
+
] is detected 






1.4 Yeast prion [PSI+] 
In this study, we focused on [PSI
+
] - prion form of Sup35. The protein Sup35 could be 
divided into three structurally and functionally distinctive domains: the N domain, the 
M domain and the C domain (see Figure 2). The N-proximal (Sup35N) domain is 
required for [PSI
+
] induction and propagation. The middle M domain (Sup35M) is 
involved in the control of stability of prion [PSI
+
]. The C-terminal domain (Sup35C) is 
essential for translation termination and viability 22 23 24. In the prion aggregates the 
sequence of N domain has been proven to be arranged in a double layer of β-sheets 
(see Figure 3 and Chapter1.1), typical for other amyloids, and each sheet is held 







Figure 2 Structural and functional organization of the Sup35 protein 





Figure 3 Structural organization of [PSI
+
]  
C-terminal domains of Sup35 (white circles) are exposed on the side. Prion domains 
(green squares) form an axis. Inset depicts a detailed structural view of the prion domain, 
that the strands of prion domain (green arrows) are parallel and precisely aligned to form 
the β-sheet.   
 
Sup35 normally works as the eukaryotic release factor eRF3. In the process of 
translational termination, eRF1 protein recognizes the stop codon and catalyzes the 
hydrolysis of the bond between the nascent polypeptide and tRNA, in which eRF3 
works as a GTPase that binds to eRF1 to facilitate the release activity. In yeast, 
mutations in the SUP35 gene result in the suppression of all three types of stop codons 
(UAA, UAG, and UGA), a phenomenon known as nonsense suppression
26 27.   
 
In the prion form most of Sup35 is aggregated, that causes the loss of its normal 
activity and nonsense-suppression in [PSI
+
] cells. The most convenient phenotypic 
 
assay for detecting [PSI
+
] is based on this effect. S. cerevisiae strains used in this study 
carry ade1-14UGA nonsense-mutation. In the mutant strain the Ade1 protein involved in 
the adenine biosynthesis is truncated and is not functional due to the premature 
translation termination. In [PSI
+
] cells, most of Sup35 is aggregated, that leads to the 
readthrough of the premature stop codon and synthesis of full-length Ade1 protein 
from ade1-14 transcript. The production of full-length Ade1 allows the strains to grow 
on media lacking adenine, the phenotype for [PSI
+
] detection in this study. In [psi
-
] 
cells, the absence of functional Ade1 protein prevents growth on media lacking 
adenine 






Figure 4 Experimental assay to detect [PSI
+
] 
A) Sup35 in the non-prion form efficiently participates in recognition of stop codons. A 
nonsense mutation in ade1-14 mRNA leads to the premature translation termination and 
synthesis of the truncated Ade1 protein. The lack of full-length Ade1 causes poor growth 
on –Ade medium and a red color of the strain on YPD. B) In [PSI+] cells, most of Sup35 is 
aggregated, that leads to the readthrough of the premature stop codon and synthesis of 
full-length Ade1 protein from ade1-14 transcript. The production of full-length Ade1 
causes growth on –Ade medium and a white color on YPD.  
 
1.5 [PSI+] and chaperon Hsp104 
Chaperones, also called heat shock proteins (Hsps), is a group of proteins that facilitate 
the proper folding of nascent proteins, prevent the aggregation of denatured and 
damaged proteins, refold misfolded proteins, and assist the degradation of proteins that 
cannot be properly refolded. Chaperones are induced when cells undergo various types 
of stresses like heat, cold, oxygen deprivation. Among different families of chaperones 
 
the three groups are the most important for prion propagation in yeast: Hsp104, Hsp70s, 
and Hsp40s 30.  
 
The first chaperone protein found to have an effect on prion was Hsp104, and it was 




. Hsp104, a homologue of 
prokaryotic ClpB, is an yeast member of the evolutionarily conserved Hsp100/ClpB 
family and acts as an ATPase in the form of homohexamer. The normal cellular 
function of Hsp104 is disaggregation of stress-damaged proteins and it is the only 
chaperone known so far to be able to act on aggregated proteins to affect their 
disaggregation, while other chaperones are believed to act by preventing the 
aggregation
32
. There is no homologue of Hsp104 found in mammals. However, with 
the importance of its ability to solubilize aggregated proteins, Hsp104 is believed to 
have a functional homologue in mammalian systems. These characteristics make the 
study of the role of Hsp104 in [PSI
+
] propagation and disaggregation so important for 
the understanding of the mechanisms of amyloid diseases.  
 
To explain the unique relationship between Hsp104 and [PSI
+
] the model based on the 
Hsp104 levels was suggested 
31,33,34
(see Figure 5). Moderate levels of Hsp104 are 
required to break the [PSI
+
] aggregates into smaller seeds which initiate new rounds of 
 
propagation. Both the depletion and overproduction of Hsp104 cure [PSI
+
]. Depletion 
of Hsp104 leads to the increase of prion aggregates in size but decrease number of 
aggregates, which reduces the efficiency of prion transmission into daughter cells and 





] “curing”). Potentially, the overproduction provides sufficient resources to 
break the aggregates into monomers that are refolded by chaperone system or degraded 
by ubiquitin-proteasome pathway. Other chaperones also have their own effects on 
[PSI
+
] curing by excess Hsp104. For examples, two sub-categories of Hsp70s family, 
Ssa and Ssb, had been shown to affect the curing when overproduced. While excess 
Ssb increases the efficiency of this [PSI
+
] curing the curing is antagonized by excess 
Ssa
35
. The complex nature of interaction of multiple chaperones with [PSI
+
] suggests 




Figure 5 Roles of Hsp104 in [PSI
+
] propagation and degradation  
A) Moderate levels of Hsp104 are needed for efficient formation of the new prion 
“seeds”. B) Inhibition or loss of Hsp104 function lead to the increase of prion 
aggregates in size but decrease number of aggregates, that reduces the efficiency of 





] “curing”). Potentially, the aggregates are broken into 
monomers that are degraded by ubiquitin-proteasome pathway or refolded by 
chaperone system. 
 
1.6 GET system  
A project was carried out in the Chernoff’s lab to find factors that regulate the curing 
of [PSI
+
] by excess Hsp104. Using EMS mutagenesis 13 colonies with the defect of 
[PSI
+
] curing by Hsp104 overexpression were isolated. One of these clones with the 
 
stronger defect of curing was found to have a premature stop codon in the nucleotide 
position 473 of the GET2 gene.  
 
Get2 is a component of the Guided Entry of Tail-anchored proteins (GET) pathway 
(see Figure 6) which is required for the targeted delivery of the Tail-anchored (TA) 
proteins from the ribosome to the endoplasmic reticulum (ER)
36
. Other known 
components of the GET pathway are Get1, Get3, Get4, Get5, and Sgt2. Newly 
synthesized TA protein is recognized by the C domain of Sgt2-Get5-Get4 complex. In 
this complex, Get5 interacts with the N domain of Sgt2 and Get4 interacts with Get5. 
Then the TA protein-Sgt2-Get5-Get4 complex is formed, in which protein components 
are centered around Sgt2. The TA protein is then handed off to Get3 which is 
stabilized in its closed conformation by Get5/Get4 for facilitating Get3-TA protein 
complex formation. The Get3-TA protein complex is recruited to the ER membrane by 
interaction with Get1/Get2 complex anchored in the ER membrane
37
. After ATP 
hydrolysis, conformational change of Get3 brings it back to the opened conformation 
and releases the TA protein which is inserted in the ER membrane. Get3 is then 
recycled
38
. In the absence of Get2 Get1/Get2 complex is not functional and 
TA-proteins fail to reach the ER membrane and form cytosolic aggregates. The 




. Sgt2 is a small glutamine-rich cytoplasmic protein described as a 
potential cochaperone since its vertebrate homologue, SGT, has been known as a 
cochaperone that regulates Hsp70s. Sgt2 contains tetratricopeptide repeats (TPR), 
which often mediate protein-protein interactions. Structurally and functionally Sgt2 
could be divided into three domains: the N-terminal domain, the middle TPR domain 
and the C-terminal domain (see Figure 7). The N domain is responsible for interaction 
with Get5.The TPR domain has sites of interaction with chaperones Hsp104/70/40s. 






Figure 6 GET pathway 
A) GET pathway is responsible for the targeted delivery of the TA proteins to the ER 
membrane. TA protein is recognized by the Sgt2-Get5-Get4 complex through a 
TA-binding domain in Sgt2. The TA protein is then handed off to Get3 which is 
stabilized in its closed conformation by Get5/Get4 for facilitating Get3-TA protein 
complex formation. B) The Get3-TA protein complex is recruited to the ER membrane 
by an interaction with Get1/Get2 complex. TA protein is then released and Get3 is 
recycled. C) In the absence of functional Get1/Get2complex TA-proteins fail to reach 
the ER membrane and form cytosolic aggregates. The cytosolic components of the 




Figure 7 Structural and functional organization of the Sgt2 protein 
N, TPR and C refer to Sgt2 N, Sgt2 TPR and Sgt2 C domains, respectively. 
 
Data obtained previously in the Chernoff’s lab showed that both mutation and deletion 
of GET2 lead to the defect of [PSI
+
] curing by excess Hsp104. Moreover, the deletions 
of components of the GET pathway, including get1∆, get2∆, get3∆, get4∆ and get5∆, 
all exhibit the similar defect. Last but not the least, get2∆ combined with sgt2∆ has a 
partial restoration to the defect. We believe that Sgt2 is the key mediator of the effect 
the defective GET pathway has on [PSI
+
] curing.. The goal of this study is to 








2.1 Yeast strains 
The only species of all the yeast used in this study is Saccharomyces cerevisiae (see 
Table 2 and Table 3). All strains, except the strains used in yeast two-hybrid assay, 
derived from GT81-1C and contain mutation ade1-14 UGA that can be suppressed in 
[PSI
+
] variants of the strains, and was used in experiments to detect the presence of the 
prion
39




Table 2 Yeast strains used as the original source for this work 
Strain  Genotype  Ref. 
GT50  MATα trp1-901 leu2-3,112 ura3-52 his3-Δ200 gal4 gal80 
Gal2-ADE2 LYS2::GAL1-HIS3 met2::GAL7-LaZ  
40
 
GT74  MATa trp1-901 leu2-3,112 ura3-52 his3-Δ200 gal4 gal80 
Gal2-ADE2 LYS2::GAL1-HIS3 met2::GAL7-LaZ  
40
 

































table # continued 








GT1487-4A MATα  ade1-14SC his3-Δ200 lys2 leu2-3,112 trp1-Δ 




]   
Not 
published 

































Table 3 Yeast strains constructed in this work 
Strain  Genotype 





]   



































]   
 
table # continued 











]   
 
Nine strains, GT1589-4A, GT1590-10C, GT1602-10B, GT1632, GT1633, GT1732, 
GT1733, GT1769, and GT1778 were constructed in this study. GT1589-4A, 
GT1590-10C, GT1602-10B, GT1632, GT1633 were created by mating GT1550 with 
GT1508-8C, GT1509-1D, GT1507-1D, GT1308 and GT1309 then tetrad dissected, 
respectively (see Chapter 2.7). GT1732 and GT1733 are [psi
-
] derivatives of GT1550 
and GT1589, respectively. [psi
-
] strains were created by overexpressing Hsp104 
(plasmid pLH105) in the original [PSI
+
] strains. Transformants were streaked on YPD 
media for ~ 5days and several colonies were picked up to check the [PSI
+
] status (on 
the media lacking adenine) and the plasmid presence (on media lacking leucine). 
  
GT1769 is a sgt2-R171A, R175A mutation strain created by Delitto Perfetto technique 
(see Chapter 2.6). GT1778 was created by mating GT1769 with GT1589 then tetrad 
dissected. GT 1589, the strain with SGT2 tagged by HA, was used to facilitate the 
selection of sgt2 mutation in the tetrad analysis. Colonies were velveteened on 
hygromycin plate (200μg/ml) to check the get2∆ and G418 (500μg/ml) plate to check 
 
sgt2 mutation (both confirmed by PCR).  
 
2.2 Plasmids 
All plasmids used in this study were produced in Escherichia coli strain DH5α (see 
Table 4 and Table 5).  
 
Table 4 Plasmids used in this study 
Plasmid  Protein  Type  Marker  Promoter  Ref. 
pRS316-GAL  Vector  CEN  URA3  PGAL  
40
 
pACT2  Vector  2µ  LEU2  PADH  
40
 
pSE1111  Snf4  2µ  LEU2  PADH  
40
 
pSE1112  Snf1  2µ  TRP1  PADH  
40
 
pGAL104-URA3  Hsp104  CEN  URA3  PGAL  
40
 
pAS1  Vector  2µ  TRP1  PADH  
40
 
pGAL::SSA1  Ssa1  CEN  URA3  PGAL  
42
 
pLH101  Ssa1  2µ  LEU2  PSSA1  
42
 
pAS1-SUP35N  Sup35N  2µ  TRP1  PADH  
40
 
pACT2-SUP35N  Sup35N  2µ  LEU2  PADH  
40
 
pG4BD-0  Vector  2µ  TRP1  PADH  
43
 
pG4BD-0-SUP35N  Sup35N  2µ  TRP1  PADH  
43
 
pRS315  Vector  CEN  LEU2  PGPD  
44
 
pLH105  Hsp104  CEN  LEU2  PGPD  
44
 
pG4BD-SUP35  Sup35  2µ  TRP1  PADH  
43
 
pG4BD-1-NMSc  Sup35NM  2µ  TRP1  PADH  Not published 
pRS315/PGAL-HSP104  Hsp104  CEN  LEU2  PGAL  Not published 
pRS316/PGPD-HSP104  Hsp104  CEN  URA3  PGPD  Not published 








Table 5 Plasmids constructed in this study 
Plasmid  Protein  Type  Marker  Promoter  
pACT2-SGT2  Sgt2  2µ  LEU2  PADH  
pAS1-SGT2  Sgt2  2µ  TRP1  PADH  
pG4BD-SGT2  Sgt2  2µ  TRP1  PADH  
 
Three plasmids, pACT2-SGT2, pAS1-SGT2, pG4BD-SGT2 were constructed in this 
study (see Figure 8). For the construction of pACT2-SGT2, the open reading frame 
(ORF) region of the SGT2 gene was PCR-amplified by using primers with the 
extensions containing the restriction sites for BamHI and XhoI (see Table 6) and then 
inserted into the polylinker of plasmids pACT2 cut by BamHI and XhoI. For 
construction of pAS1-SGT2, the ORF region of the SGT2 gene was PCR-amplified by 
using primers with the extensions containing the restriction sites for BamHI and XhoI 
and then inserted into the polylinker of plasmids pAS1 cut by BamHI and SalI. For 
construction of pG4BD-SGT2, the ORF region of the SGT2 gene was PCR-amplified 
by using primers with the extensions containing the restriction sites for BamHI and 










Table 6 Primers used in this study 
Lab# Sequence  Used for 
463 AAACGTACGACAAGAACAAG  Checking GET3 deletion (Forward)  
464 CACACACATACCATCGTATT  Checking GET3 deletion (Reverse)  
670 GATGGCTACTTGGGTTGAGC  Checking GET2 deletion (Forward)  
671 GATTTTTCACGAACTCATCGC  Checking GET2 deletion (Reverse)  
674 TGCACGTACCAACTACCTCCTG  Checking GET1 deletion (Forward)  
675 TTCAAAAGATTGGAGACGGAG  Checking GET1 deletion (Reverse)  
741  ATTGCCCTACGCTTAATCCC Checking SGT2 deletion (Forward)  
742  GTCTTCTCCGAAAATCGACG Checking SGT2 deletion (Reverse)  
754  GCTGCTCATTCATCCCTG  Sequencing SGT2 ORF. Complementary 
to the middle part of SGT2. (Forward)  
755  TTCTGGAACGGTTTTCTCC  Sequencing SGT2 ORF. Complementary 
to the middle part of SGT2 (Reverse)  
766  TAAGGATCCTCTACTGTACGATGTCAG
CATC  
Amplification of SGT2 ORF. BamHI site 




Amplification of SGT2 ORF. XhoI site is 
introduced at 3’ end of SGT2 (Reverse)  
863  CGTTAAGGTAACAAACAATGGG  Checking GET4 deletion (Forward)  
864  GGAGGCCCTTAATAGGTCTGC  Checking GET4 deletion (Reverse)  
865  GCACAGGAGAACATAGTTGGAG  Checking GET5 deletion (Forward)  
866  GAAAATAGTAAGCGCAACCG  Checking GET5 deletion (Reverse)  
876  TCAGCCCGGGATTGCTTGCTTGTTCTCA
TTGTC  
Amplification of SGT2 ORF. SmaI site is 




Amplification of the CORE cassette and 
its introduction into SGT2 gene (Forward)  
 




Amplification of the CORE cassette and 




Amplification of the fragment to 
introduce substitutions R171A, R175A in 




Amplification of the fragment to 
introduce substitutions R171A, R175A in 
SGT2 gene (Reverse)  
989 CTTATTTCGCAGGCTACTCTGC  Checking R171A,R175A mutations in 





Figure 8 Plasmids containing Sgt2 constructed for yeast two-hybrid system 
A) Full-length Sgt2 fused with Gal4 activation domain in pACT2 plasmid. B) PCR 
confirming the presence of Sgt2 in pACT2-SGT2. C) Full-length Sgt2 fused with Gal4 
DNA binding domain in pAS1 plasmid. D) PCR confirming the presence of Sgt2 in 
pAS1-SGT2. E) Full-length Sgt2 fused with Gal4 DNA binding domain in pG4BD 






Antibodies to HA epitope were purchased from COVANCE and used in 1:5000 
dilution. Antibodies to Sup35C were kindly provided Dr. David Bedwell and used in 
1:5000 dilution. Antibodies to Ade2 were raised by Cocalico Biologicals (purified 
Ade2 protein was kindly provided by V. Alenin) and used in 1:2000 dilution. 
Antibodies to Ssa were generously provided by E.Craig and used in 1:30000 dilution. 
Secondary anti-mouse and anti-rabbit antibodies were purchased from Sigma-Aldridge 
and used in 1:12000 dilution.  
 
2.4 Media and growth Conditions 
Yeast cell cultures were all grown at 30°C. Standard yeast media and standard 
procedures for yeast cultivation were used. YPG media was used to eliminate petite 
colonies from all experimental evaluations. 2% galactose instead of glucose is used in 
YPGal media to induce PGAL promoter. Liquid cultures were grown with a ~1/5 
liquid/container volume ratio in a shaking incubator (225 rpm) 46. 
 
2.5 Transformation of yeast by lithium acetate treatment 
Yeast cells are pre-cultured in 5-10mls of YPD media overnight. Pre-cultures are 
diluted with fresh YPD media (5-7 fold) and incubated at 30°C for ~5 hrs until they 
 
re-enter the exponential growth phase. Cells are collected by centrifugation at 3,000 
rpm for 5 mins, washed with H20, and resuspended in 1mls of 100mM LiAc-TE for 
one transformation. Cells are incubated for an hour with shaking at 30°C.  Afterwards, 
20g of carrier DNA and 1-10g of transforming DNA are added. Tubes are incubated 
for 30 mins at 30°C. Following the incubation, 350l per 50l of cells of 
Li-Ac-PEG-TE (40% PEG 3350, 100mM LiAc, 10mM Tris-HCl, pH7.5, 1 mM EDTA) 
is added. After half hour of incubation at 30°C, the cells are heat shocked at 42°C for 5 




2.6 Gene mutation by Delitto Perfetto 
The Delitto Perfetto technique was used in this study to introduce double point 
mutation in the chromosomal copy of SGT2 gene in the strain GT81-1C. For that the 
counterselectable reporter (CORE) cassette was amplified by using plasmid pCORE as 
a template (see Table 4). Pair of primers which are complementary to the P1, P2 (see 
Figure 9A) and also contain sequences identical to the flanking regions of the mutation 
site (see Table 6) were used for the PCR. PCR amplification of CORE cassette was 
performed with high yield in a final volume of 100μl by using Taq DNA polymerase 
(NEB) and a following program: 5 mins at 95°C, 32 cycles of 30secs at 95°C, 30secs at 
55°C, and 4 mins at 72°C by using primers 958, 959 (see Table 6). PCR product was 
 
transformed into the GT81-1C strain (see Figure 9B). Clones with the integrated 
CORE cassette were selected on -Ura media first and then double checked by their 
ability to grow on G418 media. On the next step cells with integrated CORE cassette 
were transformed with the PCR fragment identical to a region of Sgt2 with the 
designed point mutations (see Figure 9C). This transformation led to the excision of 
the CORE cassette and introduction of the mutation sgt2-R171A, R175A, which 
corresponds to substitution of arginines in positions aa171 & 175 by alanines in Sgt2 
protein. PCR amplification of this fragment was performed in a final volume of 50μl 
by using Deep Vent DNA polymerase (NEB) and a following program: 5 mins at 95°C, 
6 cycles of 10secs at 95°C, 30secs at 55°C, and 10secs at 72°C by using primers 971 
and 972 (see Table 6). Counterselection against KlURA3 marker was performed on 
5-FOA media and followed by testing for simultaneous loss of the kanMX4. The 
presence of the point mutations was confirmed by PCR with the allele-specific forward 
primer complementary to the mutation site (see Table 6) and a reverse primer 
complementary to the sequence downstream of the SGT2 ORF(see Figure 9D). PCR 
amplification of this fragment was performed with high yield in a final volume of 20μl 
by using Taq DNA polymerase and a following program: 5 min at 95°C, 30 cycles of 








Figure 9 Introduction of point mutations into SGT2 gene by Delitto Perfetto 
A) The CORE cassette for integrating two yeast markers nearby the mutation site 
(aa171 & 175) of Sgt2. The cassette was amplified by using plasmid pCORE as a 
template (Table 3) and a pair of primers which are complementary to the P1, P2 and 
also contain sequences identical to the flanking regions of the mutation site (Table 5). 
B)  PCR product was transformed into the wild type strain. Integration of the cassette 
occurs by homologous recombination within the flanking regions of the mutation site. 
Clones with the integrated CORE cassette were selected on -Ura media first and then 
double checked by their ability to grow on G418 media. C) Transformation of the cells 
with a designed PCR fragment leads to the excision of CORE cassette and substitution 
of arginines in positions aa171 & 175 by alanines. Counterselection against KlURA3 
marker was performed on 5-FOA mediam and followed by testing for simultaneous 
loss of the kanMX4. D) The presence of the point mutations was confirmed by PCR 
with the allele-specific forward primer complementary to the mutation site (Table 5) 
and a reverse primer complementary to the sequence downstream of the SGT2 ORF.   
 
 
2.7 Tetrad dissection and analysis  
Two haploid strains with opposite mating types were crossed on YPD and incubated 
for one day. Afterwards, the diploids were patched on sporulation media and incubated 
for more than 3 days until a sufficient number of cells have sporulated. Cells are then 
subjected to 40μl zymolase (0.5 mg/ml) for 2 minutes at 37
o
C to remove cell wall and 
weaken the ascus. Then a small portion of the cells are placed on YPD and dissected 
 
into their individual spores using a micromanipulator (The Singer MSM System 300). 
The spores are incubated at 30
o
C until colonies are formed. 
 
2.8 Yeast two hybrid system 
This assay (see Figure 10) was performed in two variants: in the haploid strain and in 
the diploid strain
48 49.  
 
In the haploid strains, double plasmid transformation, with both Prey and Bait, was 
performed in GT74 strain in all pair-vise combinations. Eight colonies were selected 
from each transformation plates and were patched onto media lacking leucine and 
tryptophan. These plates were cultured for ~2 days, and were then replica-plated onto 
YPD, media lacking adenine, media lacking both leucine and tryptophan, and YPG.  
The protein interaction was estimated by examining the growth on media lacking 
adenine after ~4 days. 
 
In diploid strains, strain GT74 was transformed by pACT2-based plasmids (Prey) and 
strain GT50 was transformed by pG4BD-based plasmids (Bait) in all pair-vise 
combinations. Two colonies were selected from each transformation plates and were 
patched onto media lacking leucine or tryptophan. These plates were cultured for ~2 
 
days, and then cells were patched onto media lacking both leucine and tryptophan for 
mating. Each two colonies of GT74 transformants were mated with each two colonies 
of GT50 transformants, thus giving four diploid strains for every Prey-Bait 
combination. Diploids were selected on media lacking both leucine and tryptophan and 
were then replica-plated on YPD, media lacking adenine, media lacking both leucine 
and tryptophan, and YPG. The protein interaction was estimated by examining the 





Figure 10 Overview of yeast two hybrid (Y2H) assay 
A) Gal4 transcription factor consists of two domains (BD and AD) which are both 
essential for transcription of the reporter gene (ADE2). B) To check if two proteins 
(called Bait and Prey here) interact with each other two fusion constructs are prepared: 
Gal4BD+Bait and Gal4AD+Prey. None of them is sufficient for initiating the 
transcription of ADE2 alone. C) When both fusion proteins are produced and Bait 
interacts with Prey, the transcription of ADE2 begins.  
 
 
2.9 Yeast protein isolation  
All the cell cultures were grown at 30°C till the OD600 reached 0.4-0.5. Cell pellets 
were collected by centrifugation at 3000 rpm for 5 mins. To isolate proteins, cell 
pellets were resuspended in lysis buffer (50mM Tris-Cl pH 7.5, 200mM NaCl, 1 % 
Triton X-100, 0.1%SDS, 1mM EDTA, 1mM PMSF in Complete
TM
 protease inhibitor 
cocktail (Roche). Acid-washed glass beads were added and the solution was vortexed 
for 1 min for 5 times with 1 min on ice between vortexing. To collect total lysates, cell 
debris was removed by centrifugation at 6000 rpm for 2 min. The protein concentration 
was estimated by Bradford assay.  
 
2.10 SDS-PAGE and Western-blotting 
Protein was mixed with 1/3 volume of 4X loading buffer (600Mm Tris-Cl pH6.8, 12% 
SDS, 40% glycerol 12% 2-mercaptoethanol and 0.6% bromophenol blue) and boiled 
for 5 min. After boiling, the protein sample was loaded on the 10% 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Electrophoresis was performed 
at 100 volts for 2 hour. After the electrophoresis, proteins were transferred from the 
gels to a PVDF membrane (Immobilon-P Membrane, Millipore) using the tank 
electroblotting system (Bio-Rad). Before transfer, the PVDF was incubated first in 
methanol and then in transfer buffer (10% methanol, 10mM CAPS, pH11.0). Also, the 
 
gel was incubated in transfer buffer before the transfer. The transfer was performed at 
4°C, 275mA for 45 mins. Appropriate primary antibodies then were used to perform 
Western-blotting analysis. Then the membranes were probed with appropriate 
secondary antibodies and developed according to the Amersham ECL detection system 
protocols (250mM luminal, 90mM coumaric acid, 0.03% H2O2, 0.1 m Tris pH8.5). 
 
2.11 Co-Immunoprecipitation of proteins interacting with Sgt2 
All the cell cultures were grown at 30°C till the OD600 reached 0.4-0.5. Cell pellets 
were collected by centrifugation at 3000 rpm for 5 mins. To isolate proteins, cell 
pellets were resuspended in lysis buffer (75mM KCl, 25mM Tris, 0.5% Triton X-100, 
pH 7.0, 1mM PMSF in Complete
TM
 protease inhibitor cocktail (Roche). Acid-washed 
glass beads were added and the solution was vortexed for 1 min for 5 times with 1 min 
on ice between vortexing. To collect total lysates, cell debris was removed by 
centrifugation at 1000 rpm for 10 min at 4°C. The protein concentration was estimated 
by Bradford assay. 
 
The fallowing steps (see Figure 12A) were performed at 4°C. Protein lysate was first 
incubated with HA antibody (Ab) overnight. Then the Ab-protein complex was 
captured by 2 hours incubation with protein-A agarose. . Afterwards, the resin was 
 
washed 3 times by PBS (137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4 1.47mM 
KH2PO4 pH 7.0). Wash buffer was removed by centrifugation at 1000 rpm for 2 mins. 
Identification of proteins in the pellet was performed by Western-blotting. 
 
2.12 Curing of [PSI+] by Hsp104 overproduction 
2.12.1  Qualitative curing of [PSI
+
] by Hsp104 expressed from GPD promoter 
To overproduce Hsp104, strains were transformed with the plasmid containing HSP104 
gene under PGPD promoter. Four colonies were selected for each transformation and 
were patched onto synthetic media according to the yeast maker of that plasmid. Plates 
were incubated for ~ 3 days, and then were replica-plated onto YPD, the relative 
synthetic media, the relative synthetic media also lacking adenine, and YPG. YPD and 
the relative synthetic media were used to control growth rate and plasmid maintaining. 
YPG media was used to eliminate petite clones from experimental evaluation. The 
curing was estimated by examining the growth on that relative synthetic media also 
lacking adenine after ~5 days. 
 
2.12.2 Qualitative curing of [PSI
+
]by Hsp104 expressed from GAL promoter 
To overproduce Hsp104, strains were transformed with the plasmid containing HSP104 
gene under PGAL promoter. Four colonies were selected for each transformation and 
 
were patched onto synthetic media relative to the yeast maker of that plasmid. Plates 
were incubated for ~ 3 days, and then were velveteened onto YPGal media and 
incubated for one day. Cells were then repatached on the relative synthetic media and 
incubated for 2 days. These plates were then velveteened on YPGal again (2
nd
 round 
induction) and incubated for one day. Cells were then repatached on the relative 
synthetic media. These plates were cultured for ~ 3 days, and then were replica-plated 
onto YPD, the relative synthetic media, the relative synthetic media also lacking 
adenine, and YPG. YPD and the relative synthetic media were used to control growth 
rate and plasmid maintaining. YPG media was used to eliminate petite colonies from 
experimental evaluation. The curing was estimated by examining the growth on that 




3.1 The physical interaction between Sgt2 and Sup35 
The effect of sgt2∆ on [PSI
+
] curing in the strain with defective GET system could be 
explained by three different mechanisms. First, Sgt2 can potentially interact with [PSI
+
] 
aggregates and change its properties. Second, Sgt2 might be needed for chaperones to 
interact with [PSI
+
]. Third, Sgt2 might prevent chaperones from interaction with [PSI
+
] 
by retargeting them into a different pathway. 
The first two models suggest a direct or indirect interaction of Sgt2 with [PSI
+
] . If one 
of these two models is correct we would expect Sgt2 to interact with Sup35. 
 
3.1.1 Interaction between Sgt2 and Sup35 in yeast two-hybrid system 
To check if Sgt2 can interact with Sup35 we used yeast two hybrid (Y2H) system to 
test the interaction between Sgt2 and full length Sup35, and its truncated versions (N 
domain and NM domain). This assay was performed in two variants: in the haploid 
strain and in the diploid strain (see Chapter 2.9). Comparison of the interaction in both 
variants of the assay will allow us to decrease the probability of false positive or false 
negative results.   
 
 
In the haploid strains, double plasmid transformation, with both Prey and Bait, was 
performed in GT74 strain in all pair-vise combinations. Eight colonies were selected 
from each transformation plates and were patched onto media lacking leucine and 
tryptophan. These plates were cultured for ~2 days, and were then replica-plated onto 
YPD, media lacking adenine, media lacking both leucine and tryptophan, and YPG.  
The protein interaction was estimated by examining the growth on media lacking 
adenine after ~4 days. 
 
The results (see Figure11A and Table 7) suggest a relatively weak but detectable 
interaction between full-length Sgt2 (as Bait) and N-terminal domain of Sup35 (as 
Prey). If Sup35 was used as Bait, the results demonstrated interaction of Sup35 or 
Sup35N with all Prey constructs (including empty vector as negative control). No 
interaction was detected for Sup35NM as Bait with any other constructs including 










+  =  Stronger growth  
+ -  =  Normal growth  
- +  =  Weaker growth  




To test the interaction between Sgt2 and Sup35 in diploid strains, strain GT74 was 
transformed by pACT2-based plasmids (Prey) and strain GT50 was transformed by 
pG4BD-based plasmids (Bait) in all pair-vise combinations. Two colonies were 
selected from each transformation plates and were patched onto media lacking leucine 
or tryptophan. These plates were cultured for ~2 days, and then cells were patched onto 
media lacking both leucine and tryptophan for mating. Each two colonies of GT74 
transformants were mated with each two colonies of GT50 transformants, thus giving 
four diploid strains for every Prey-Bait combination.  Diploids were selected on 
media lacking both leucine and tryptophan and were then replica-plated on YPD, 
 
media lacking adenine, media lacking both leucine and tryptophan, and YPG. The 
protein interaction was estimated by examining the growth on media lacking adenine 
after ~ 5 days. 
 
The growth of diploids containing Sgt2 (as Bait) and Sup35N (as Prey) (see Figure 
11B and Table 8) suggests the interaction between these two proteins. In case if 
Sup35N served as Bait, the results again demonstrated interaction with all used Prey 
constructs (including empty vector as negative control). 
 




+  =  Stronger growth  
+ -  =  Normal growth  
- +  =  Weaker growth  




The growth of the strains carrying both Sgt2 and Sup35N constructs is much weaker 
compared to the growth of the strains with Snf1 and Snf4 used as a positive control, 
that suggests that the interaction between Sgt2 and Sup35 is relatively weak or 
transient. The similar results for Sgt2 interaction with Sup35N in both diploid and 
haploid strains in Y2H strongly suggest that this interaction is genuine. However, the 
Sgt2 self- interaction could be only detected in the haploid strain.  
 
 
Figure 11 Interaction between Sgt2 and Sup35 in Y2H  
A) Double plasmids transformation was performed in GT74 strain. The transformants 
were patched on -Trp-Leu media and replica plated to -Ade media. Image was taken 
after ~4 days of incubation. The growth of the strains indicates interaction between 
respective proteins. B) GT74 was transformed by pACT2-based plasmids and GT50 
was transformed by pG4BD-based plasmids in all pair-vise combinations. The 
transformants of each strain were patched on –Trp-Leu medium for mating. Diploids 
then picked and patched on -Trp-Leu media and replica plated to -Ade media. Image 
was taken after ~5 days of incubation. The growth of the strains indicates interaction 
between respective proteins. 
 
 
3.1.2 Interaction between Sgt2 and Sup35 shown by co-immunoprecipitation 
To verify the data obtained in Y2H assay we examined the interaction between Sgt2 protein and 





] strains were examined and compared. We performed this assay in both wild type 
and get2∆ strains to check if defect of the GET pathway changes the efficiency of this interaction.  
 
Since the interaction between Sgt2 and Sup35 is relatively weak, we optimized the Co-IP protocol 
used in this study to detect even very low amounts of interacting proteins (see Chapter 2.11). A 
low-salt lysis buffer was used to avoid the disruption of interactions while preparing the protein 
lysate and a very “soft” wash buffer was used to clean the resin without breaking the specific 
interaction between proteins. A low speed centrifugation is required from the very first step of the 
resin cleaning to prevent a contamination of the samples with precipitated [PSI
+
] aggregates.  
 





strains, supporting the previous results obtained in Y2H assay that native Sup35 interacts with 
Sgt2. Also these results show that not only the native form but also the prion form of Sup35 
interacts with Sgt2. We observed that the amount of Sup35 interacting with Sgt2 in [PSI
+
] strains 
is higher than in [psi
-
]. This is an expected effect that matches either two mechanisms we 




aggregates will sequester Sgt2 by its direct or indirect interaction with the prion form of Sup35.  
 
By comparing the results from wild type and get2∆ strains, the portion of Sup35 interacting with 
Sgt2 in get2∆ strain is smaller than in wild type strain. Moreover, Sgt2 has a higher expression in 
get2∆ strain than in wild type (also see Figure 13 and Chapter 3.2.1). A possible reason for the 
decreased amount of the Sup35 interacting with Sgt2 is that part of Sgt2 is sequestered by the TA 
protein aggregates caused by defect in the GET pathway in get2∆ strain. Aggregation of Sgt2 
prevents it interaction with other proteins including Sup35. 
 
To make sure that Sup35 expression maintains at the same level in each strain, the 
immunoblotting of the same protein lysates used for Co-IP was done for comparing the Sup35 
levels. The result showed that the expressions of Sup35 are approximately equal in all strains 
which means the portion of Sup35 interacting with Sgt2 depends on the levels of Sgt2 and 





Figure 12 Co-immunoprecipitation of Sup35 with Sgt2 
A) The overview of co-immunoprecipitation (Co-IP) of the proteins interacting with 
HA-tagged Sgt2. HA antibodies (Ab) are added to the protein lysate. Then the 
Ab-protein complex is pelleted using protein-A agarose. Sgt2-interacting proteins will 
be precipitated with Ab-Sgt2 complex. Identification of proteins in the pellet was 
performed by Western-blotting. B) The Interaction between Sgt2 and Sup35 detected 
by Co-IP. The result shows that smaller portion of Sup35 interacts with Sgt2 in get2∆ 





] cells. The protein lysate controls at the bottom panel show the approximately equal 
level of Sup35 in each strain. 
    
 
 
3.2 Sgt2 levels depend on the functional GET pathway and [PSI+] status of the 
strain  
The expression of chaperones and co-chaperones changes in response to the 
aggregation of the misfolded proteins accumulating in the cytoplasm. We addressed 
 
the question if Sgt2 (described as a potential co-chaperone) levels depend on the 
presence of GET/TA aggregates and/or [PSI
+
] aggregates in the cells. 
 
3.2.1 Sgt2 levels are higher in the strains with defective GET pathway 
The Co-IP experiments (see Figure 12) suggest that Sgt2 has a higher expression level 
in get2∆ than in wild type strain. We addressed the question if Sgt2 levels are also 
increased in other get∆ strains or it is specific for get2∆ only.  
 
Protein lysates from wild type, get1∆, get2∆, get3∆, get4∆ and get5∆ strains were 
isolated and compared by the Sgt2 levels using Western blotting (see Chapter 2.10). 
The results (see Figure 13) showed that there is more Sgt2 in any get∆ stain compared 
to the wild type, especially in get2∆. It suggests that high Sgt2 expression level is a 
result of the defect in the GET pathway regardless of the GET gene deleted. Still, 
deletions of individual GET components have different levels of Sgt2 overproduction 





Figure 13 Sgt2 levels are higher in the strains with defective GET pathway  
Wild type, get1∆, get2∆, get3∆, get4∆ and get5∆ strains were compared by the Sgt2 
levels. Sgt2 was fused to the HA tag and detected by hybridization with anti-HA 
antibodies. Ade2 was used as a loading control. The result shows that there is more 
Sgt2 is in the cell in any get∆ stain than in wild type, especially in get2∆. 
 
3.2.2 Sgt2 levels depend of [PSI
+





] variants of get2∆ and wild type strains were also compared by the 
Sgt2 levels using the standard Western-blotting protocol (see Chapter 2.10). The result 
(see Figure14) showed that levels of Sgt2 are higher in [PSI
+
] cells compared to the 
isogenic [psi
-
] cells regardless of the status of the GET pathway. It suggests that any 









] variants of get2∆ and wild type strains were compared by the Sgt2 
levels. Sgt2 was fused to the HA tag and detected by hybridization with anti-HA 
antibodies. Ade2 was used as a loading control. [PSI
+
] cells generate more Sgt2 than 
[psi
-








3.3 Sgt2 indirectly assists Ssa in protection of [PSI+] from the curing  
Data obtained previously in the Chernoff’s lab showed that overproduction of Sgt2 
itself does not cause any defect in [PSI
+
] curing. There must be other protein(s), 
involved in this process to protect [PSI
+
] from curing. The most likely candidates for 
the protein causing [PSI
+
] curing defect are chaperones Hsp70-Ssa that are known to 





3.3.1 Sgt2 overproduction increases the effect of Ssa1 on [PSI
+
] protection  
The previous results obtained in the Chernoff’s lab show that depletion of Sgt2 greatly 
 
reduces the protective effect of Ssa1 overproduction of [PSI
+
] curing. We addressed 
the question if physical interaction between Sgt2 and Ssa is needed for [PSI
+
] 
protection from curing. For that we used site-directed mutagenesis to substitute 
arginines in the positions 171 and 175 in Sgt2 to alanines. This double mutation is 
known to disrupt completely the interaction between Sgt2 and chaperones Hsp104 and 
Hsp70 (Ssa). Thus, protein Sgt2-R171A, R175A cannot interact with chaperones 
through its TPR domain but still has functional N and C terminal domains. 
 
We tested the [PSI
+
] curing efficiency in the strain bearing chromosomal mutation 
sgt2-R171A, R175A in comparison to sgt2∆ and wild-type strains with or without 
overproduction of Ssa1 in the presence of excess Hsp104.  
 
For overproduction of both Ssa1 and Hsp104, the sgt2∆, sgt2-R171A, R175A, and wild 
type strains were transformed by two plasmids: one for Ssa1 overproduction and the 
other for Hsp104 overproduction. Experiment was performed in two independent sets 
different by the promoter that controlled the expression of HSP104 and SSA1. In the 
first set pRS316/PGPD-HSP104 plasmid (with URA3 marker) contained HSP104 gene 
under the strong constitutive PGPD promoter, and pLH101 multicopy 2µ plasmid (with 
LEU2 marker) had SSA1 gene under its own promoter. In the second set, 
 
pRS316/PGAL-HSP104 (with LEU2 marker) and pGAL::SSA1 (with URA3 marker) 
plasmids contained HSP104 and SSA1 genes, respectively, under galactose inducible 
promoter PGAL. 
 
Four colonies were selected from each transformation and were patched onto media 
lacking leucine and uracil. For the first set plates were incubated for ~ 3 days, and then 
were replica-plated onto YPD, media lacking leucine and uracil, media lacking adenine 
and leucine and uracil, and YPG. The curing was estimated by examining the growth 
on media lacking adenine and leucine & uracil after ~5 days. For PGAL set plates were 
incubated for ~ 3 days, and then were velveteened onto YPGal media and incubated for 
one day. Cells were then repatached on media lacking leucine and uracil and incubated 
for 2 days. These plates were then velveteened onto YPGal again (2
nd
 round of 
induction) and incubated for one day. Cells were then repatached on media lacking 
leucine and uracil. These plates were cultured for ~ 3 days, and were then 
replica-plated onto YPD, media lacking leucine and uracil, and media lacking adenine 
and leucine and uracil. The curing was estimated by examining the growth on media 
lacking adenine and leucine and uracil after ~5 days.  
 




from curing by excess Hsp104 in the sgt2-R171A, R175A strain to the extent of the 
same effect observed in the wild type strain(see Figure 15). Meanwhile, in the sgt2∆ 
strain protection was not efficient. Taken together, our results prove that Sgt2 assists 
Ssa in the protection of [PSI
+
] from curing by excess Hsp104. Moreover, this effect 
does not require the direct interaction between Sgt2 and Ssa. 
 
 
Figure 15 The effect of disrupting the interaction between Sgt2 and chaperones on 
the protection of [PSI
+
] curing by overexpressed Ssa  
Comparison of the efficiency of [PSI
+
] protection by overexpressed Ssa in wild type 
strain and strains lacking Sgt2 or having mutant form of Sgt2. Expression of HSP104 
was controlled by either strong constitutive (PGPD) or strong inducible (PGAL) 
promoters. The results show that sgt2-R171A, R175A has no effect on protection of 
[PSI
+





3.3.2  Protection of [PSI
+
] from curing in get2∆ strain depends on levels of Sgt2 
and Ssa 
We suggested that the defect of [PSI
+
] curing in the strains with the defect of the GET 
pathway is observed due to both Sgt2 and Ssa overproduction. If this hypothesis is 
correct we should see the [PSI
+
] protection in the strains with get2∆ having both Sgt2 
and Ssa overproduction. According to the unpublished data obtained in the Chernoff’s 
lab, in the strain with defect in the GET pathway levels of both Sgt2 and Ssa are 
increased. We predicted that in get2∆ strain Sgt2 will be overproduced even if Sgt2 has 
point mutation preventing it from interactions with chaperones and the defect of [PSI
+
] 
curing will be observed. To test this prediction we constructed a strain that combines 
get2∆ and sgt2-R171A, R175A mutation. Six strains, get2Δ, sgt2∆, get2Δsgt2∆, 
sgt2-R171A, R175A and get2Δ sgt2-R171A, R175A alone with the wild type control 
were compared by the efficiency of [PSI
+
] curing and Ssa levels.  
 
To verify our hypothesis, the first thing needed to be confirmed is that the get2Δ 
sgt2-R171A, R175A strain has high levels of Ssa. Protein lysates from six strains 
mentioned above were isolated and compared by the Ssa1 levels by using the standard 
Western-blotting protocol (see Chapter 2.10).  
 
Results (Fig.16) show that all get2Δ strains regardless of the SGT2 state (get2Δ, get2Δ 
 
sgt2Δ, and get2Δ sgt2-R171A, R175A) have excess Ssa1 comparing to GET2 strains 
(wild type, sgt2Δ, and sgt2-R171A, R175A). As we expected, Ssa was overproduced in 
the get2Δ sgt2-R171A, R175A strain.  
 
Figure 16 The effect of SGT2 deletion and mutation on Ssa1 levels 
The levels of Ssa1 were compared in wild type and get2∆strains, bearing SGT2 
deletion or mutation. Ade2 was used as a loading control. Result showed that get2Δ 
strains have excess Ssa1 comparing to those GET2 strains. 
 
Next we compared the efficiency of [PSI
+
] curing in the same set of strains to examine 
the effect sgt2-R171A, R175A mutation. This experiment was performed in the 
qualitative curing of [PSI
+
] by Hsp104 expressed under either PGPD or PGAL promoters. 
To overproduce Hsp104, those six strains were transformed with the plasmid 
pRS316/PGPD-HSP104 containing HSP104 gene under PGPD promoter or plasmid 
 
pGAL104-URA3 with HSP104 gene under PGAL promoter. 
 
Four colonies were selected for each transformation and were patched onto media 
lacking uracil. For the first set, plates were incubated for ~ 3 days, and then were 
replica-plated onto YPD, media lacking uracil, media lacking adenine and uracil, and 
YPG. The curing was estimated by examining the growth on media lacking adenine 
and uracil after ~5 days. For the second set, plates were incubated for ~ 3 days, and 
then were velveteened onto YPGal media and incubated for one day. Cells were then 
repatached on media lacking uracil and incubated for 2 days. These plates were then 
velveteened onto YPGal again (2
nd
 round induction) and incubated for one day. Cells 
were then repatached on media lacking uracil. These plates were incubated for ~ 3 days, 
and were then replica-plated on YPD, media lacking uracil, and media lacking adenine 
and uracil. The curing was estimated by examining the growth on media lacking 
adenine and uracil after ~5 days. 
 
In the both sets of the experiment, we observed the similar results (see Figire17). The 
comparison of the strain sgt2-R171A, R175A with wild type control shows that the 
disruption of interaction between Sgt2 and chaperones does not have its own effect on 
either maintaining [PSI
+
] status or [PSI
+
] curing by excess Hsp104. By comparing the 
 
get2Δ sgt2-R171A, R175A strain with the get2Δstrain and the wild type control, it 
shows that this get2Δ sgt2-R171A, R175A strain also has a defect of [PSI
+
] curing and 
suggests that the interaction between Sgt2 and Ssa is not needed for the protection of 
[PSI
+
] from curing. Taking these results together with the Sgt2 and Ssa levels of these 
strains, a conclusion could be made that the protection of [PSI
+
] from curing in get2∆ 
strain depends on the simultaneous overproduction of Sgt2 and Ssa. The direct 








Figure 17 The effect of disrupting the interaction between Sgt2 and chaperones on 
[PSI
+
] curing   
Comparison of the efficiency of [PSI
+
] curing in wild type and get2∆ strains lacking 
Sgt2 or having mutant form of Sgt2. Expression of HSP104 was controlled by either 
strong constitutive (PGPD) or strong inducible (PGAL) promoters. In the first case strains 
were transformed with pRS316/PGPD-HSP104 or control plasmid, patched on-Ura 
media and incubated for ~3 days. The -Ura plate was replica plated to -Ura-Ade and 
incubated for ~5 days. In the second case strains were transformed with 
pGAL104-URA3 or control plasmids, patched on -Ura media and incubated for ~3 
days. The -Ura media was replicated to YPGal and incubated for 1day. Cells were then 
repatched on –Ura and incubated for 2 days. The -Ura media was replicated to YPGal 
again and incubated for 1day. Cells were then repatached again on –Ura and incubated 
for 2 days. The -Ura plate was replica plated to -Ura-Ade and incubated at 30°C for ~5 
days. The results show that by themselves, both sgt2∆ and sgt2-R171A, R175A have no 
effect on [PSI
+
] curing. In get2∆ strains, sgt2∆ has a restoration to the defect of [PSI
+
] 
curing but sgt2-R171A, R175A doesn’t.  
 
4 Discussion 
Multiple works from different labs suggest that prion [PSI
+
] is controlled by the 
ensemble of chaperones with Hsp104 playing the major role
42,50,51
. Changes in the 
chaperone balance affect [PSI
+
] stability, and/or induction, and/or curing. The previous 
work performed in the Chernoff’s lab showed that the defect in the GET pathway 
caused by get2∆ led to the defect in [PSI
+
] curing by excess Hsp104. In this study we 
prescribe the mechanism underlying the effect of get2∆ on [PSI
+
]. We demonstrate that 
overproduction of Ssa and Sgt2 is triggered by inactivation of the GET pathway and 
leads to the protection of [PSI
+
] aggregates from curing. The Sgt2 overproduction is 
required in this case since a big part of Sgt2 may be sequestered by the TA/GET 
aggregates.   
 
The initial step of this chain of events is a deletion of the GET2 gene needed for the 
proper delivery of the TA proteins to the endoplasmic membrane. The exact 
mechanism that triggers the Ssa and Sgt2 induction is unknown. We believe it has a 
direct connection to the formation of the aggregates of TA proteins in the cytoplasm of 
the mutant cells. TA proteins have a stretch of hydrophobic amino acids on their 
C-terminal end
52
. Normally, these proteins are delivered rapidly to the ER membrane 
and are anchored into it. If GET pathway has a defect in function, the TA proteins are 
 
expected to be accumulated in the cytoplasm
36
. Due to the presence of the exposed 
hydrophobic stretches TA proteins form aggregates that also include TA-interacting 
proteins. Sgt2 is a protein that normally interacts with the hydrophobic tail of TA 
proteins and it is sequestered in the GET/TA aggregates (Chernoff’s lab unpublished 
data) together with Get3, Get4, and Get5. Ssa chaperones are able to bind hydrophobic 
sequences of the misfolded proteins and assist in their refolding or targeting to a 
certain compartment 
30,53,54
. We believe that formation of the GET/TA aggregates 
triggers the non-specific cellular stress response and overproduction of the Ssa in order 
to protect the cell from accumulation of the misfolded proteins. This hypothesis is 
supported by the fact that Hsp104 is also overproduced in get2∆ cells (Chernoff’s lab 
unpublished data). It is still not clear if Sgt2 overproduction is a result of the 
non-specific stress response in the cells or it is triggered specifically by the defect in 
the GET pathway. Either way, our data show that the direct interaction between Ssa 
and Sgt2 is not needed to protect [PSI
+
] from curing. So, Sgt2 is not a co-chaperone of 
Ssa at least in Ssa interaction with [PSI
+
] aggregates. To explain their combined action 
on [PSI
+
] we propose the following model (Fig.18). We assume that Sgt2 protein 
changes the conformation of the β-sheet core of [PSI
+
], which makes the Ssa protection 
from Hsp104 curing more efficient.  
 
 
Figure 18 Model for Sgt2’s role in the prion curing by Hsp104 
Sgt2 protein changes the conformation of β-sheet of [PSI
+
], which makes the Ssa 
protein easier to protect the fibrillar structure from Hsp104 curing.  
 
This mechanism of [PSI
+
] protection has a universal mechanism and can be observed 
not in get2∆ strains only. The deletions of components of the GET pathway, including 
get1∆, get3∆, get4∆, and get5∆, all exhibit the similar defect of [PSI
+
] curing. We also 
showed that Sgt2 is overproduced to a different extent in all of these strains. Moreover, 
the Ssa levels are also higher in all of get∆ strains (Chernoff’s lab unpublished data). 
Taken together, our data show a good correlation between the high levels of Ssa and 





More experiments are to be done to examine our conclusion and model. First we need 
to find the domain of Sgt2 responsible for the interaction between Sup35 and Sgt2 and 
the positions of amino acids crucial for it. A strain with the disrupted interaction then 
will be created and we will check the [PSI
+
] curing under Ssa overproduction. 
Afterwards, we need to create a strain with disrupted interaction between Sup35 with 
Sgt2 in get2∆ then check the [PSI
+
] curing in this strain. If we are correct, strains with 
disrupted interaction between Sup35 with Sgt2 will have the same phenotype just like 
sgt2∆ stains. The deletion of Ssa will be not be adopted to this study since single 
deletion of any of the Ssa protein will not have any effect and a total deletion of Ssa 
will cause cell death. However, we can construct plasmid with mutated SSA having 
disrupted interaction with Sup35 or Hsp104 under strong constitutive or inducible 
promoter. For this purpose, we also need to find out the position of amino acid in SSA 
responsible for that. Overproducing these mutated Ssas and normal Sgt2 at the same 
time can help us clarify how Ssa protect [PSI
+
] together with Sgt2.    
   
Ssa may not be the only chaperone involved this Sgt2-chperones-[PSI
+
] machinery 
dependant on defective GET pathway. Unpublished data form Chernoff’s lab had 
already shown that Hsp104 maintains its function and Hsp40s are not involved in this 
 
mechanism. But we haven’t excluded the possibility that there are other chaperones 
involved in. It is known that the Ssb can facilitate the curing of [PSI
+
]. Ssb 
overproduction increases, while Ssb depletion decreases, [PSI] curing by the 
overproduced Hsp104
42
. Although it is shown that no Ssb is observed in GET/TA 
aggregates (Chernoff’s lab unpublished data), there is still a chance that Sgt2 can block 
the function of Ssb to halt the curing process.  
 
In the Y2H experiment, the Sgt2 self interaction could be detected only in the haploid 
strain. This self interaction is not confirmed yet and this is one of the important issues 
to know how Sgt2 functions. If Sgt2 interacts with itself, the conformation change of 
the dimer of polymer form of Sgt2 may be responsible for changing the conformation 
of [PSI
+
]. BiFC and FRET are potential methods to answer this question
55 56. Moreover, 
constructions of plasmids with the full length SUP35 as Prey and truncated SGT2 as 
either Prey or Bait are important tasks in the future. Full-length Sup35 construction as 
Bait didn’t provide us interpretable data, and we need to verify the interaction between 
Sgt2 and full-length Sup35. Constructions of truncated SGT2 with only N or TPR or C 
domain will provide us information about in which domain Sgt2 interacts with Sup35.  
 
However, Y2H could only be used to detect the interaction between Sgt2 and native 
 
form of Sup35. Constructions of strains with truncated Sgt2 tagged with HA will 
provide us information of in which domain Sgt2 interacts with [PSI
+
] by Co-IP method. 
 
The results (see Chapter 3.2.2 and Figure 14) suggest that not only GET pathway 
affects [PSI
+
] but also [PSI
+
] may affect GET pathway. Since Sgt2 is induced in [PSI
+
] 




I. Sgt2 interacts with Sup35 in both [PSI+] and [psi-] strains 
 
II. Sgt2 interacts with Sup35N  
 
III. Sgt2 levels are higher in the strains with the defective GET pathway 
 
IV. Sgt2 assists Ssa in protection of [PSI+] from curing 
 
V. The direct interaction between Sgt2 and Ssa is not required for the protection of 
[PSI+] from curing 
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